论文部分内容阅读
用佳代胞（ＰＶＩ）对４５例恶性胸腔积液患者进行Ⅲ期临床验证。将ＰＶＩ（２ｍｇ／ｍｌ）１～３ｍｌ注入胸腔内，变动体位，１次／周，共２次。结果：全组ＣＲ５１．１％（２３／４５），ＰＲ３１．１％（８／４５），有效率（ＣＲ＋ＰＲ）为８２．２％（３７／４５）。不良反应：恶心３７．８％，呕吐１５．６％，食欲不振６０％，发热８４．４％，胸痛８０．０％，白细胞升高（１００００～２８０００）６０％，胸水癌细胞阴转率为９２．８％（２６／２８）。ＰＶＩ治疗后Ｂ超和胸片证实均有不同程度的胸膜增厚。结果说明佳代胞的疗效明显（８２．２％），副反应不严重，可作为治疗恶性胸腔积液的有效药物。
Forty-five patients with malignant pleural effusion underwent phase Ⅲ clinical trial with good cell (PVI). The PVI (2mg / ml) 1 ~ 3ml into the chest, changes in position, 1 / week, a total of 2 times. Results: The overall CR51.1% (23/45), PR31.1% (8/45), effective rate (CR + PR) was 82.2% (37/45). Adverse reactions: nausea 37.8%, vomiting 15.6%, loss of appetite 60%, fever 84.4%, 80.0% of chest pain, leukocytosis (10000 ~ 28000) 60%, negative conversion rate of pleural fluid cancer cells 92.8% (26/28). After PVI B ultrasound and chest X-ray confirmed varying degrees of pleural thickening. The results show that the effect of Ji Daili significant (82.2%), the side effects are not serious, can be used as an effective treatment of malignant pleural effusion.